Technical Analysis for RCEL - Avita Medical Limited

Grade Last Price % Change Price Change
F 8.87 -5.44% -0.51
RCEL closed down 5.44 percent on Thursday, April 18, 2024, on 1.47 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 9
*** please verify all earnings dates ***
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction -5.44%
Lower Bollinger Band Walk Weakness -5.44%
Wide Bands Range Expansion -5.44%
Oversold Stochastic Weakness -5.44%
Slingshot Bearish Bearish Swing Setup -8.56%
Calm After Storm Range Contraction -8.56%

   Recent Intraday Alerts

Alert Time
Down 5% about 19 hours ago
Lower Bollinger Band Support about 19 hours ago
60 Minute Opening Range Breakdown about 21 hours ago
Down 3% about 21 hours ago
Fell Below Previous Day's Low about 22 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Avita Medical Limited Description

Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients 18 years and older. The company has a preclinical research collaboration with the University of Colorado School of Medicine to establish and explore development of a spray-on treatment for patients with epidermolysis bullosa. The company is based in Valencia, California.


Classification

Sector: Healthcare
Industry: Medical Devices
Keywords: Medicine Clinical Medicine Rare Diseases Clinical Research Dermatology Wound Suspension Regenerative Medicine Platform Technology Burns Genodermatoses Aesthetics Epidermolysis Bullosa Skin Chronic Wound Chronic Wounds Treatment Solutions

Is RCEL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 21.704
52 Week Low 8.78
Average Volume 238,878
200-Day Moving Average 14.69
50-Day Moving Average 15.80
20-Day Moving Average 13.74
10-Day Moving Average 11.76
Average True Range 0.90
RSI (14) 15.97
ADX 46.11
+DI 6.77
-DI 46.74
Chandelier Exit (Long, 3 ATRs) 13.95
Chandelier Exit (Short, 3 ATRs) 11.48
Upper Bollinger Bands 19.25
Lower Bollinger Band 8.23
Percent B (%b) 0.06
BandWidth 80.18
MACD Line -1.87
MACD Signal Line -1.25
MACD Histogram -0.621
Fundamentals Value
Market Cap 226.63 Million
Num Shares 25.6 Million
EPS -1.34
Price-to-Earnings (P/E) Ratio -6.62
Price-to-Sales 10.13
Price-to-Book 7.30
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.83
Resistance 3 (R3) 9.91 9.66 9.67
Resistance 2 (R2) 9.66 9.42 9.63 9.62
Resistance 1 (R1) 9.27 9.27 9.15 9.19 9.56
Pivot Point 9.02 9.02 8.96 8.99 9.02
Support 1 (S1) 8.63 8.78 8.51 8.55 8.18
Support 2 (S2) 8.38 8.63 8.35 8.12
Support 3 (S3) 7.99 8.38 8.07
Support 4 (S4) 7.91